5.72 USD
+0.88
18.18%
At close Apr 23, 4:00 PM EDT
After hours
5.69
-0.03
0.52%
1 day
18.18%
5 days
30.00%
1 month
41.23%
3 months
43.36%
6 months
108.76%
Year to date
85.11%
1 year
308.57%
5 years
-62.17%
10 years
-69.21%
 

About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Employees: 209

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

25% more capital invested

Capital invested by funds: $19.8M [Q3] → $24.8M (+$5.01M) [Q4]

18% more funds holding

Funds holding: 34 [Q3] → 40 (+6) [Q4]

2.52% less ownership

Funds ownership: 36.77% [Q3] → 34.25% (-2.52%) [Q4]

43% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 14

81% less call options, than puts

Call options by funds: $5K | Put options by funds: $26K

Research analyst outlook

We haven’t received any recent analyst ratings for XGN.

Financial journalist opinion

Neutral
GlobeNewsWire
2 days ago
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT).
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
Neutral
Seeking Alpha
1 month ago
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript
Exagen Inc. (NASDAQ:XGN ) Q4 2024 Results Conference Call March 11, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Matthew Parisi - KeyBanc Operator Greetings, and welcome to Exagen Inc. Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript
Neutral
Zacks Investment Research
1 month ago
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.31 per share a year ago.
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Neutral
GlobeNewsWire
1 month ago
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market opens on Tuesday, March 11, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 AM ET (5:30 AM PT).
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
Positive
Zacks Investment Research
2 months ago
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
Neutral
GlobeNewsWire
2 months ago
Exagen Inc. to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences:
Exagen Inc. to Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
3 months ago
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) biomarker assays, with a planned commercial launch in January 2025.
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
Neutral
GlobeNewsWire
4 months ago
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
Neutral
GlobeNewsWire
5 months ago
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Charts implemented using Lightweight Charts™